Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial

NCT06245356 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06245356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06245356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
March 21, 2025
Completion date
October 21, 2028
Enrollment
73 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

dpd deficiency, metastatic colorectal cancer, metastatic gastroesophageal adenocarcinoma